Trametinib DMSO solvate - CAS# 1187431-43-1 Catalog No.:M10955-10 Smiles: CC(C)(O)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2/C(/CCC[C@@]21C)=C/C=C1/C[C@@H](O)CCC/1=C

Smiles: CC(C)(O)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2/C(/CCC[C@@]21C)=C/C=C1/C[C@@H](O)CCC/1=C

InChiKey: HZASIAXCPXTISQ-NVXWUHKLSA-N

1) and 5-HT-evoked increases in intracellular calcium (pIC50 = 10

InChi: InChI=1S/C23H11ClN4/c24-15-8-9-18-19(10-15)16-6-1-2-7-17(16)21-22(18)28-23(27-21)20-13(11-25)4-3-5-14(20)12-26/h1-10H

Formula: C20H25Cl2N3O2S

Trametinib DMSO solvate - CAS# 1187431-43-1 Catalog No.:M10955-10 Smiles: CC(C)(O)[C@@H](O)CC[C@@H](C)[C@H]1CC[C@H]2/C(/CCC[C@@]21C)=C/C=C1/C[C@@H](O)CCC/1=CTrametinib, also known as GSK1120212, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in various cancer cell